CSIMarket
 


Oncternal Therapeutics Inc   (ONCT)
Other Ticker:  
 

Oncternal Therapeutics Inc 's Leverage Ratio

ONCT's quarterly Leverage Ratio and Total Liabilities, Equity growth


Due to net new borrowings of 12.14%, Leverage Ratio fell to 0.16, below the Oncternal Therapeutics Inc 's average Leverage Ratio.

Within Major Pharmaceutical Preparations industry in the third quarter 2023, 71 other companies have achieved lower Leverage Ratio than Oncternal Therapeutics Inc in the III Quarter 2023. While Leverage Ratio total ranking has improved so far in the third quarter 2023 to 212, from total ranking in the second quarter 2023 at 234 .

Explain Leverage Ratio?
Who are ONCT Customers?
What are ONCT´s Total Liabilities?


ONCT Leverage Ratio (Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity Change -46.03 % -38.94 % -34.55 % -30.81 % -27.45 %
Y / Y Total Liabilities Change -21.95 % -29.11 % 9.14 % 8.66 % 31.63 %
Leverage Ratio MRQ 0.16 0.12 0.11 0.12 0.11
ONCT's Total Ranking # 212 # 234 # 134 # 310 # 274
Seq. Equity Change -18.12 % -13.92 % -13.91 % -11.05 % -7.37 %
Seq. Total Liabilities Change 12.14 % -9.07 % -24.37 % 1.21 % 1.85 %



Leverage Ratio third quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 72
Healthcare Sector # 118
Overall Market # 212


Leverage Ratio Statistics
High Average Low
16.23 0.85 0.03
(Dec 31 2015)   (Mar 31 2019)




Financial Statements
Oncternal Therapeutics Inc 's Equity $ 37 Millions Visit ONCT's Balance sheet
Oncternal Therapeutics Inc 's Total Liabilities $ 6 Millions Visit ONCT's Balance sheet
Source of ONCT's Sales Visit ONCT's Sales by Geography


Cumulative Oncternal Therapeutics Inc 's Leverage Ratio

ONCT's Leverage Ratio for the trailling 12 Months

ONCT Leverage Ratio

(Sep 30 2023)
III. Quarter
(Jun 30 2023)
II. Quarter
(Mar 31 2023)
I. Quarter
(Dec 31 2022)
IV. Quarter
(Sep 30 2022)
III. Quarter
Y / Y Equity TTM Growth -46.03 % -38.94 % -34.55 % -30.81 % -27.45 %
Y / Y Total Liabilities TTM Growth -21.95 % -29.11 % 9.14 % 8.66 % 31.63 %
Leverage Ratio TTM 0.12 0.11 0.11 0.1 0.09
Total Ranking TTM # 227 # 233 # 230 # 225 # 213
Seq. Equity TTM Growth -18.12 % -13.92 % -13.91 % -11.05 % -7.37 %
Seq. Total Liabilities TTM Growth 12.14 % -9.07 % -24.37 % 1.21 % 1.85 %


On the trailing twelve months basis Due to the net new borrowings of 12.14% during the trailing twelve months finishing in the III Quarter 2023, cumulativeLeverage Ratio improved to 0.12, below the Oncternal Therapeutics Inc 's average Leverage Ratio.
Leverage Ratio is the average cumulative value over the last four quarters.

Among companies in the Major Pharmaceutical Preparations industry ONCT recorded the lowest Leverage Ratio. While Leverage Ratio total ranking has improved so far to 2, from total ranking in previous 12 month period at 196.

Explain Leverage Ratio?
Who are ONCT Customers?
What are ONCT´s Total Liabilities?

TTM Leverage Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Within the Market # 212


trailing twelve months Leverage Ratio Statistics
High Average Low
1.74 0.29 0.06
(March 31, 2016)   (Sep 30 2021)




Companies with similar Leverage Ratio in the quarter ending Sep 30 2023, within Major Pharmaceutical Preparations Industry Leverage RatioSep 30 2023 MRQ Total LiabilitiesSep 30 2023 MRQ Equity
Opko Health Inc   0.42 $ 612.112  Millions$ 1,444.568  Millions
Arrowhead Pharmaceuticals Inc   0.42 $ 121.275  Millions$ 287.162  Millions
Integrated Biopharma Inc  0.41 $ 7.756  Millions$ 18.886  Millions
Geron Corp  0.41 $ 119.224  Millions$ 290.614  Millions
Oncolytics Biotech Inc   0.41 $ 8.623  Millions$ 21.113  Millions
Azitra Inc   0.40 $ 2.158  Millions$ 5.332  Millions
Vera Therapeutics Inc   0.40 $ 49.393  Millions$ 123.707  Millions
Alaunos Therapeutics Inc   0.40 $ 5.540  Millions$ 13.900  Millions
Aclaris Therapeutics Inc   0.39 $ 61.711  Millions$ 156.333  Millions
Arcus Biosciences Inc   0.38 $ 200.000  Millions$ 520.000  Millions
Biomarin Pharmaceutical Inc  0.38 $ 1,861.266  Millions$ 4,896.897  Millions
Nkarta Inc   0.37 $ 109.048  Millions$ 296.816  Millions
Immunic Inc   0.37 $ 17.781  Millions$ 48.407  Millions
Bolt Biotherapeutics Inc   0.37 $ 47.096  Millions$ 128.259  Millions
Cymabay Therapeutics Inc   0.36 $ 119.022  Millions$ 326.191  Millions
Ampio Pharmaceuticals inc   0.36 $ 1.909  Millions$ 5.375  Millions
Pyxis Oncology Inc   0.35 $ 48.746  Millions$ 137.946  Millions
Genprex Inc   0.35 $ 4.338  Millions$ 12.305  Millions
Dyne Therapeutics Inc   0.35 $ 53.206  Millions$ 152.038  Millions
Universe Pharmaceuticals Inc  0.35 $ 13.754  Millions$ 39.533  Millions
Kamada Ltd   0.34 $ 83.972  Millions$ 244.021  Millions
Lumos Pharma Inc   0.34 $ 12.133  Millions$ 35.492  Millions
Genelux Corporation  0.34 $ 8.150  Millions$ 24.028  Millions
Galecto Inc   0.34 $ 12.667  Millions$ 37.382  Millions
Regulus Therapeutics Inc   0.34 $ 9.488  Millions$ 28.259  Millions
Briacell Therapeutics Corp   0.33 $ 0.841  Millions$ 2.516  Millions
Kronos Bio Inc   0.33 $ 59.373  Millions$ 178.620  Millions
Verve Therapeutics Inc   0.33 $ 152.038  Millions$ 460.369  Millions
Arbutus Biopharma Corp  0.33 $ 39.304  Millions$ 119.337  Millions
Biohaven Ltd   0.32 $ 92.730  Millions$ 290.006  Millions

Date modified: 2024-01-10T05:56:45+00:00



Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com